dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Patient Education

  • There is no clear evidence of specific association between lifestyle factors and dyspepsia, but some individuals may be helped by these measures
  • To reduce anxiety in cases where there are no indications of organic disease, reassurance is an important part of initial therapy
  • Provide patients with access to educational materials to support the care they receive and emphasize adherence to medical therapy

Lifestyle Modification

  • Advise patients to avoid known precipitants that they associate with dyspeptic symptoms eg alcohol, coffee, chocolate and fatty foods
    • Alcohol, coffee, and chocolate have pharmacological effects that may reduce the tone of the lower esophageal sphincter (LES)
    • Fatty foods delay gastric emptying time which may also predispose to GERD
  • Encourage patient to stop smoking
    • Smoking has pharmacological effects that may reduce the tone of the LES
  • Weight reduction for overweight and obese patients
    • Obesity may disrupt the LES due to mechanical pressure on the diaphragm
  • May suggest having a main meal well before going to bed (preferably 3 hours before)
  • Some patients may benefit from raising the head when sleeping
    • Lying flat may increase reflux episodes since gravity does not prevent acid regurgitation

Other Considerations

  • If there is concurrent use of NSAIDs, evaluate for risk of GI complications and consider alternative strategies if risk is a concern, eg use of enteric-coated NSAIDs 
    • See Peptic Ulcer Disease Disease Management Chart for details
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.